Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DALIAH low-dose interferon-alpha in Danish Ph-negative chronic myeloid neoplasms
2011-001919-31Phase 3Completed
- Sponsor
- Zealand University Hospital, Roskilde
- Start
- Aug 2011
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of interferon alfa, peginterferon alfa-2b and hydroxyurea in thrombocythemia, polycythemia vera (PV), primary myelofibrosis (PMF) and 1 more (3 arms), sponsored by Zealand University Hospital, Roskilde. Primary endpoint: Molecular response (primary). Started Aug 2011; status: completed.
02
Drugs
interferon alfapeginterferon alfa-2bhydroxyurea
03
Conditions
thrombocythemiapolycythemia vera (PV)primary myelofibrosis (PMF)chronic myelogenous leukemia (CML)
Beyond the preview
Go deeper on 2011-001919-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-001919-31.